Prostate Cancer Foundation of Australia
Services offered
Prostate cancer often grows slowly and has one of the highest survival rates if it’s diagnosed early.
The most common tests for diagnosing prostate cancer are PSA blood tests, mpMRI scans and digital rectal examinations.
Your doctors will look at the stage (how far the cancer has spread), the grade (how the cells look compared to normal cells) and the risk of progression if it is a localised (early) prostate cancer. This will help them work out which management or treatment options to recommend.
There is no simple test to find prostate cancer. Commonly used tests include the PSA blood test, mpMRI scan and digital rectal examination (DRE). These tests, used separately or together, may only show prostate changes – they don’t always diagnose prostate cancer. If an abnormality is found, you may have more tests or a biopsy.
Health professionals use Australian clinical guidelines to help decide when to use PSA testing and other early tests for prostate cancer.
These tests help your doctors work out if you have prostate cancer and whether it has spread. Working out how far the cancer has spread is called staging. It helps your doctors recommend the best treatment for you.
The most common staging system for prostate cancer is the TNM system. In this system, letters and numbers are used to describe the cancer, with higher numbers indicating larger size or spread.
Your doctor may also describe the cancer as:
The biopsy results will show the grade of the cancer. Grading describes how the cancer cells look under a microscope compared to normal cells.
For many years, the Gleason scoring system has been used to grade the tissue taken during a biopsy. If you have prostate cancer, you will have a Gleason score between 6 (slightly abnormal) and 10 (more abnormal). A newer system has been introduced to simplify the grading and make it easier to understand. Known as the International Society of Urological Pathologists (ISUP) Grade Group system, this grades prostate cancer from 1 (least aggressive) to 5 (most aggressive).
Localised (early) prostate cancer is given a risk of progression that helps to guide treatment. The risk level is based on the size and grade of the cancer, and your PSA level before the biopsy (see table below):
| Risk level | Gleason score | ISUP Grade Group |
| low | 6 or less | 1 |
| intermediate | 7 | 2-3 |
| high | 8-10 | 4-5 |
Your PSA level and the tumour (T) size also help work out the cancer’s risk level.
Prognosis means the expected outcome of a disease. You can talk about your prognosis and treatment options with your doctor, but they can’t predict the exact course of the disease. They can give you an idea about the general outlook for people with the same type and stage of cancer.
To work out the prognosis, your doctor will consider your test results, the type of prostate cancer, the stage, grade and risk of progression, how well you respond to treatment, and your age, fitness and medical history.
Prostate cancer often grows slowly – even aggressive cases of prostate cancer tend to grow more slowly than other types of cancer. Some low-risk prostate cancers grow so slowly that they never cause any symptoms or spread; others don’t grow at all. Compared with other cancers, prostate cancer has one of the highest survival rates if diagnosed early.
The stage, grade and risk of progression of prostate cancer is complex, so ask your doctor to explain how it applies to you. Call Cancer Connect on 13 11 20 for information and support.
Prostate Cancer Foundation of Australia
Services offered
Find the right services for your needs, wherever you are in Australia
Trusted cancer information for all people affected by cancer
We're available 9am - 5pm, Monday to Friday (excluding public holidays)